
## Iluminada Corripio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8408069/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Resting-state functional connectivity alterations in the default network of schizophrenia patients with persistent auditory verbal hallucinations. Schizophrenia Research, 2015, 161, 261-268.	2.0	106
2	Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. Schizophrenia Research, 2015, 164, 65-73.	2.0	92
3	Mobile Phone and Wearable Sensor-Based mHealth Approaches for Psychiatric Disorders and Symptoms: Systematic Review. JMIR Mental Health, 2019, 6, e9819.	3.3	90
4	Cognitive reserve as an outcome predictor: firstâ€episode affective versus nonâ€affective psychosis. Acta Psychiatrica Scandinavica, 2018, 138, 441-455.	4.5	66
5	Randomized control trial to assess the efficacy of metacognitive training compared with a psycho-educational group in people with a recent-onset psychosis. Psychological Medicine, 2017, 47, 1573-1584.	4.5	64
6	Altered default network resting state functional connectivity in patients with a first episode of psychosis. Schizophrenia Research, 2012, 139, 13-18.	2.0	56
7	Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. Schizophrenia Research, 2018, 193, 188-196.	2.0	50
8	Deep brain stimulation in treatment resistant schizophrenia: A pilot randomized cross-over clinical trial. EBioMedicine, 2020, 51, 102568.	6.1	50
9	The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. Schizophrenia Research, 2017, 189, 84-90.	2.0	49
10	Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. Psychopharmacology, 2006, 189, 145-153.	3.1	43
11	Altered amplitude of low frequency fluctuations in schizophrenia patients with persistent auditory verbal hallucinations. Schizophrenia Research, 2017, 189, 97-103.	2.0	43
12	Modelling gene-environment interaction in first episodes of psychosis. Schizophrenia Research, 2017, 189, 181-189.	2.0	43
13	SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. Journal of Nuclear Medicine, 2005, 46, 1301-9.	5.0	41
14	ls cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?. Psychological Medicine, 2018, 48, 2247-2256.	4.5	40
15	Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. NeuroImage, 2006, 29, 662-666.	4.2	38
16	Examining Gene–Environment Interactions Using Aggregate Scores in a First-Episode Psychosis Cohort. Schizophrenia Bulletin, 2020, 46, 1019-1025.	4.3	32
17	Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 699-711.	3.2	31
18	Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. Pharmacogenomics Journal, 2016, 16, 439-445.	2.0	30

Iluminada Corripio

#	Article	IF	CITATIONS
19	Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. Journal of Psychopharmacology, 2008, 22, 882-894.	4.0	29
20	One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. Psychiatry Research, 2012, 200, 693-701.	3.3	29
21	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. International Journal of Neuropsychopharmacology, 2016, 19, pyv121.	2.1	29
22	Persistent Negative Symptoms in First-Episode Psychosis. Journal of Clinical Psychiatry, 2017, 78, 1414-1422.	2.2	28
23	Clinical Improvement in a Treatment-Resistant Patient With Schizophrenia Treated With Deep Brain Stimulation. Biological Psychiatry, 2016, 80, e69-e70.	1.3	27
24	Cannabis use, COMT, BDNF and age at first-episode psychosis. Psychiatry Research, 2017, 250, 38-43.	3.3	26
25	Affective versus non-affective first episode psychoses: A longitudinal study. Journal of Affective Disorders, 2018, 238, 297-304.	4.1	26
26	Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism. NeuroImage: Clinical, 2016, 11, 770-779.	2.7	25
27	Volumetric and morphological characteristics of the hippocampus are associated with progression to schizophrenia in patients with first-episode psychosis. European Psychiatry, 2017, 45, 1-5.	0.2	25
28	Measuring Users' Receptivity Toward an Integral Intervention Model Based on mHealth Solutions for Patients With Treatment-Resistant Schizophrenia (m-RESIST): A Qualitative Study. JMIR MHealth and UHealth, 2016, 4, e112.	3.7	23
29	Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History. PLoS ONE, 2016, 11, e0160949.	2.5	22
30	The functioning assessment short test (FAST) applied to first-episode psychosis: Psychometric properties and severity thresholds. European Neuropsychopharmacology, 2021, 47, 98-111.	0.7	21
31	Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique. European Neuropsychopharmacology, 2021, 47, 112-129.	0.7	20
32	Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 1231-IBZM study with ziprasidone and haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 91-96.	4.8	19
33	Dopamine D2 receptor occupancy by risperidone: Implications for the timing and magnitude of clinical response. Psychiatry Research - Neuroimaging, 2006, 148, 175-183.	1.8	19
34	Substance Use in Patients With First-Episode Psychosis: Is Gender Relevant?. Journal of Dual Diagnosis, 2015, 11, 153-160.	1.2	19
35	Density of striatal D2 receptors in untreated first-episode psychosis: An I123-IBZM SPECT study. European Neuropsychopharmacology, 2011, 21, 861-866.	0.7	17
36	Association of the <i>brain-derived neurotrophic factor</i> Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders. European Psychiatry, 2016, 38, 61-69.	0.2	17

ILUMINADA CORRIPIO

#	Article	IF	CITATIONS
37	The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses. Psychological Medicine, 2022, 52, 526-537.	4.5	17
38	Trajectories of suicidal ideation after firstâ€episode psychosis: a growth mixture modeling approach. Acta Psychiatrica Scandinavica, 2021, 143, 418-433.	4.5	17
39	Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis. European Neuropsychopharmacology, 2019, 29, 786-794.	0.7	16
40	Gray and white matter changes and their relation to illness trajectory in first episode psychosis. European Neuropsychopharmacology, 2018, 28, 392-400.	0.7	15
41	Widespread Increased Diffusivity Reveals Early Cortical Degeneration in Huntington Disease. American Journal of Neuroradiology, 2019, 40, 1464-1468.	2.4	15
42	Double-Blind, Placebo-Controlled Study of the Efficacy of Reboxetine and Citalopram as Adjuncts to Atypical Antipsychotics for Negative Symptoms of Schizophrenia. Journal of Clinical Psychiatry, 2014, 75, 608-615.	2.2	15
43	Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. Schizophrenia Research, 2022, 243, 32-42.	2.0	15
44	The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: Iodine-123-iodobenzamide single photon emission computed tomography study. Psychiatry Research - Neuroimaging, 2012, 201, 73-77.	1.8	14
45	Exploring Risk and Resilient Profiles for Functional Impairment and Baseline Predictors in a 2-Year Follow-Up First-Episode Psychosis Cohort Using Latent Class Growth Analysis. Journal of Clinical Medicine, 2021, 10, 73.	2.4	14
46	Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: An in vivo SPECT study. Schizophrenia Research, 2011, 129, 169-171.	2.0	13
47	Gene-environment interaction as a predictor of early adjustment in first episode psychosis. Schizophrenia Research, 2017, 189, 196-203.	2.0	13
48	Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. European Neuropsychopharmacology, 2017, 27, 647-656.	0.7	13
49	Smoking does not impact social and non-social cognition in patients with first episode psychosis. Schizophrenia Research, 2018, 199, 64-74.	2.0	13
50	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 164-176.	1.8	13
51	Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 767-770.	4.8	12
52	Predictors of schizophrenia in patients with a first episode of psychosis. Psychiatry Research, 2010, 175, 11-14.	3.3	12
53	Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. Journal of Psychopharmacology, 2020, 34, 514-523.	4.0	12
54	The effect of family environment and psychiatric family history on psychosocial functioning in first-episode psychosis at baseline and after 2 years. European Neuropsychopharmacology, 2021, 49, 54-68.	0.7	12

ILUMINADA CORRIPIO

#	Article	IF	CITATIONS
55	Mobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST): a prospective multicentre feasibility study protocol in patients and their caregivers. BMJ Open, 2018, 8, e021346.	1.9	11
56	Target selection for deep brain stimulation in treatment resistant schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 112, 110436.	4.8	11
57	Clinical and serotonergic predictors of nonâ€affective acute remitting psychosis in patients with a firstâ€episode psychosis. Acta Psychiatrica Scandinavica, 2009, 119, 71-77.	4.5	10
58	The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis. Journal of Clinical Medicine, 2021, 10, 2474.	2.4	10
59	Predictors of response to pharmacological treatments in treatment-resistant schizophrenia – A systematic review and meta-analysis. Schizophrenia Research, 2021, 236, 123-134.	2.0	10
60	Cognitive clusters in first-episode psychosis. Schizophrenia Research, 2021, 237, 31-39.	2.0	10
61	Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLiM): justificación, objetivos, diseño y descripción de la muestra. Revista De PsiquiatrÃa Y Salud Mental, 2014, 7, 166-178.	1.8	9
62	Emotional fMR auditory paradigm demonstrates normalization of limbic hyperactivity after cognitive behavior therapy for auditory hallucinations. Schizophrenia Research, 2018, 193, 304-312.	2.0	9
63	Structural brain abnormalities in borderline personality disorder correlate with clinical severity and predict psychotherapy response. Brain Imaging and Behavior, 2021, 15, 2502-2512.	2.1	9
64	Letter to the Editor: Deep brain stimulation for schizophrenia. Journal of Neurosurgery, 2016, 125, 229-230.	1.6	8
65	Impact of <i>NTRK2, DRD2</i> and <i>ACE</i> polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis. Journal of Psychopharmacology, 2018, 32, 702-710.	4.0	8
66	Brain metabolic changes in patients with treatment resistant schizophrenia treated with deep brain stimulation: A series of cases. Journal of Psychiatric Research, 2020, 127, 57-61.	3.1	8
67	Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. Schizophrenia Research, 2020, 218, 292-294.	2.0	6
68	Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2014, 7, 166-178.	0.3	5
69	Grey matter microstructural alterations in schizophrenia patients with treatment-resistant auditory verbal hallucinations. Journal of Psychiatric Research, 2021, 138, 130-138.	3.1	5
70	Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis. Schizophrenia Research, 2021, 236, 19-28.	2.0	5
71	m-RESIST, a complete m-Health solution for patients with treatmentresistant schizophrenia: a qualitative study of user needs and acceptability in the Barcelona metropolitan area. Actas Espanolas De Psiquiatria, 2017, 45, 277-89.	0.1	5
72	The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory. Psychological Medicine, 2021, 51, 2044-2053.	4.5	4

ILUMINADA CORRIPIO

#	Article	IF	CITATIONS
73	Is the effect of cognitive reserve in longitudinal outcomes in first-episode psychoses dependent on the use of cannabis?. Journal of Affective Disorders, 2022, 302, 83-93.	4.1	4
74	The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study. European Neuropsychopharmacology, 2022, 57, 105-117.	0.7	4
75	Positive and Useful Voices in Patients With Schizophrenia. Journal of Nervous and Mental Disease, 2020, 208, 587-592.	1.0	3
76	A Method to Compare the Delivery of Psychiatric Care for People with Treatment-Resistant Schizophrenia. International Journal of Environmental Research and Public Health, 2020, 17, 7527.	2.6	3
77	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 164-176.	0.3	3
78	Validation of a Spanish version of the Schizotypal Personality Questionnaire (SPQ): Psychometric characteristics and underlying factor structure derived from a healthy university student sample. Actas Espanolas De Psiquiatria, 2018, 46, 159-73.	0.1	2
79	The network structure of cognitive deficits in first episode psychosis patients. Schizophrenia Research, 2022, 244, 46-54.	2.0	2
80	Different measures for auditory hallucinations in populations with psychosis. The Validation of the Spanish versions of the Auditory Vocal Hallucination Rating Scale (AVHRS) and the Positive and Useful Voices Inquiry (PUVI). Revista De PsiquiatrÃa Y Salud Mental, 2022, 15, 259-271.	1.8	1
81	T237. USER EXPERIENCE TOWARDS AN INTEGRAL INTERVENTION MODEL BASED ON M-HEALTH SOLUTION FOR PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA (M-RESIST): QUALITATIVE INFORMATION FROM PATIENTS, CAREGIVERS AND CLINICIANS IN A PILOT STUDY. Schizophrenia Bulletin, 2018, 44, S208-S209.	4.3	0
82	F245. COGNITIVE RESERVE DIFFERENCE IN AFFECTIVE AND NONAFFECTIVE PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S318-S318.	4.3	0
83	S229. THE EFFECT OF FAMILY ENVIRONMENT ON LONGITUDINAL FUNCTIONING IN FIRST PSYCHOTIC EPISODES. Schizophrenia Bulletin, 2020, 46, S125-S126.	4.3	0
84	Structure and Functioning of Acute Inpatient Psychiatric Units in Spain: Qualitative Study. JMIR Research Protocols, 2021, 10, e26214.	1.0	0